2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

he Journal of the Americ e American College of C published on behalf of t uwer. This is an open acce tribution Non-Commerci n, and reproduction in operly cited, the use is no made. This document was approv ustees and the American H mmittee in November 201 ue of this guideline. Neil J. Stone, MD, MACP, FAHA, FACC, Chair Jennifer G. Robinson, MD, MPH, FAHA, Vice Chair Alice H. Lichtenstein, DSC, FAHA, Vice Chair

[1]  R. Brook,et al.  Secondary causes of dyslipidemia. , 2012, The American journal of cardiology.

[2]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[3]  C. E. Becker.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.

[4]  A. Gotto,et al.  Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. , 2010, The American journal of cardiology.

[5]  N. Wenger,et al.  End-of-life decision making , 2000, Journal of General Internal Medicine.

[6]  M. Tinetti,et al.  Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. , 2011, Archives of internal medicine.

[7]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[8]  Diane Lacaille,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk , 2014 .

[9]  R. Collins,et al.  Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial , 2010, The Lancet.

[10]  Harlan M Krumholz,et al.  Cardiac care for older adults. Time for a new paradigm. , 2011, Journal of the American College of Cardiology.

[11]  J. Hippisley-Cox,et al.  Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD. , 2005, The British journal of general practice : the journal of the Royal College of General Practitioners.

[12]  M. Hennerici,et al.  Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack , 2009, Neurology.

[13]  P. Macfarlane,et al.  Pravastatin and cognitive function in the elderly. Results of the PROSPER study , 2009, Journal of Neurology.

[14]  C. White,et al.  Impact of statin dosing intensity on transaminase and creatine kinase. , 2007, The American journal of medicine.

[15]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[16]  S. Studenski,et al.  Angiotensin‐Converting Enzyme Inhibitor and Statin Use and Incident Mobility Limitation in Community‐Dwelling Older Adults: The Health, Aging and Body Composition Study , 2011, Journal of the American Geriatrics Society.

[17]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[18]  H. Origasa,et al.  Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). , 2003, American heart journal.

[19]  Jennifer G. Robinson,et al.  Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly? , 2007, Stroke.

[20]  Janusz Wnek,et al.  2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[21]  R. Varadhan,et al.  Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines , 2013, BMC Medicine.

[22]  S. Greenfield,et al.  COMMITTEE ON STANDARDS FOR DEVELOPING TRUSTWORTHY CLINICAL PRACTICE GUIDELINES , 2011 .

[23]  G. Alexander,et al.  Reconsidering medication appropriateness for patients late in life. , 2006, Archives of internal medicine.

[24]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[25]  J. Crouse,et al.  Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. , 1987, The American journal of medicine.

[26]  R. Eckel,et al.  Treatment of hypertriglyceridemia , 2006, National Institutes of Health consensus development conference summary.

[27]  A. Laupacis,et al.  Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[29]  Judith S. Hochman,et al.  Reprint: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. , 2013, Journal of the American Pharmacists Association : JAPhA.

[30]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[31]  G. Thompson.  Recommendations for the use of LDL apheresis. , 2008, Atherosclerosis.

[32]  M. Rawlins.  De testimonio: on the evidence for decisions about the use of therapeutic interventions , 2008, The Lancet.

[33]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[34]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[35]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[36]  M. Jessup,et al.  The next steps in developing clinical practice guidelines for prevention. , 2013, Journal of the American College of Cardiology.

[37]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[38]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[39]  Marilyn Rantz,et al.  Predicting death in the nursing home: development and validation of the 6-month Minimum Data Set mortality risk index. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[40]  L. Cho,et al.  Asian Americans and cardiometabolic risk why and how to study them. , 2010, Journal of the American College of Cardiology.

[41]  M. Roffi,et al.  Current concepts on coronary revascularization in diabetic patients. , 2011, European heart journal.

[42]  N. Stone,et al.  Goals of statin therapy: three viewpoints. , 2004, Current atherosclerosis reports.

[43]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[44]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[45]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[46]  Robert J. Glynn,et al.  Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial , 2010, Annals of Internal Medicine.

[47]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[48]  F. Veglia,et al.  Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis? , 2011, Heart.

[49]  B. Starfield,et al.  Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. , 2002, Archives of internal medicine.

[50]  L. Castilla-Guerra,et al.  EFFECT OF ATORVASTATIN IN ELDERLY PATIENTS WITH A RECENT STROKE OR TRANSIENT ISCHEMIC ATTACK , 2009, Neurology.

[51]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[52]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[53]  D. Mikhailidis,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) , 2006, Diabetes Care.

[54]  The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. , 1984, JAMA.

[55]  J. Stamler.  Clofibrate and niacin in coronary heart disease. , 1975, JAMA.

[56]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[57]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[58]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[59]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[60]  A. Hartmann,et al.  Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[61]  F. Messerli,et al.  Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis. , 2008, The American journal of cardiology.

[62]  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[63]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[64]  M. Barry,et al.  Shared decision making--pinnacle of patient-centered care. , 2012, The New England journal of medicine.

[65]  N. Paynter,et al.  Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. , 2011, Archives of internal medicine.

[66]  N. Stone,et al.  Management of lipids in clinical practice , 1997 .

[67]  Samy I McFarlane,et al.  High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. , 2008, Journal of the cardiometabolic syndrome.

[68]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[69]  D. Pryor,et al.  Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. , 1995, JAMA.

[70]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[71]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[72]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[73]  Elizabeth H Bradley,et al.  Understanding the treatment preferences of seriously ill patients. , 2002, The New England journal of medicine.

[74]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[75]  I. Holme,et al.  Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. , 2007, The American journal of cardiology.

[76]  S. Bonovas,et al.  Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. , 2007, British journal of clinical pharmacology.

[77]  D. Capuzzi,et al.  Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.

[78]  Irene M Stratton,et al.  Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. , 2004, Diabetes care.

[79]  W. Lewis,et al.  Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. , 2010, Preventive cardiology.

[80]  R. Eckel.  Approach to the patient who is intolerant of statin therapy. , 2010, The Journal of clinical endocrinology and metabolism.

[81]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[82]  R. Collins,et al.  Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.

[83]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[84]  Edward J. Mills,et al.  Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. , 2008, Journal of the American College of Cardiology.

[85]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[86]  D. Schwertz,et al.  High-Dose Statin Therapy for Secondary Prevention of Stroke: Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study Review , 2008, The Journal of cardiovascular nursing.

[87]  H. Shimomura,et al.  Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. , 2006, The American journal of cardiology.

[88]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[89]  D. Hunninghake,et al.  Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. , 2004, Journal of the American College of Cardiology.

[90]  J. Danks,et al.  Fates worse than death: the role of valued life activities in health-state evaluations. , 1996, Health Psychology.

[91]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[92]  Adolescents.  Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2011, Pediatric Clinical Practice Guidelines & Policies.

[93]  S. Grundy,et al.  Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.

[94]  A. Cass.  Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.

[95]  M. Clearfield.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes. , 2005, Current atherosclerosis reports.

[96]  M. Lauer,et al.  Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. , 2013, Journal of the American College of Cardiology.

[97]  O. Faergeman,et al.  Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). , 2009, The American journal of cardiology.

[98]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[99]  F. Sacks,et al.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[100]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[101]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[102]  J. Kastelein,et al.  Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. , 2008, Mayo Clinic proceedings.

[103]  Dawei Xie,et al.  All‐Cause 1‐, 5‐, and 10‐Year Mortality in Elderly People According to Activities of Daily Living Stage , 2012, Journal of the American Geriatrics Society.

[104]  Y. Ohashi,et al.  Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study) , 2008, Circulation.

[105]  H. Bays,et al.  Safety considerations with niacin therapy. , 2007, The American journal of cardiology.

[106]  L. Prosser,et al.  Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[107]  E. Braunwald,et al.  Coronary heart disease Acute coronary syndromes and diabetes : is intensive lipid lowering beneficial ? Results of the PROVE IT-TIMI 22 trial , 2006 .

[108]  Sharp Collaborative Group.  Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.

[109]  Roger B. Davis,et al.  External Validation of an Index to Predict Up to 9‐Year Mortality of Community‐Dwelling Adults Aged 65 and Older , 2011, Journal of the American Geriatrics Society.

[110]  M. Tinetti,et al.  Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. , 2011, Archives of internal medicine.

[111]  D. Herrington,et al.  Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease , 2007, Annals of Internal Medicine.

[112]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[113]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[114]  A. Yashin,et al.  Age Patterns of Incidence of Geriatric Disease in the U.S. Elderly Population: Medicare‐Based Analysis , 2012, Journal of the American Geriatrics Society.

[115]  W. Howard.  Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study , 2008 .

[116]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[117]  Paul M. Ridker,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[118]  K. Bainey,et al.  Increased burden of coronary artery disease in South-Asians living in North America. Need for an aggressive management algorithm. , 2009, Atherosclerosis.

[119]  B. G. Brown,et al.  Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. , 2008, The American journal of cardiology.

[120]  D. Simons-Morton,et al.  Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2016, Pediatric Clinical Practice Guidelines & Policies.

[121]  L. Goldman,et al.  Adolescent overweight and future adult coronary heart disease. , 2007, The New England journal of medicine.

[122]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[123]  A. LaCroix,et al.  Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[124]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[125]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[126]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[127]  M. Landray,et al.  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.

[128]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[129]  J Wouter Jukema,et al.  Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. , 2010, Archives of internal medicine.

[130]  J. Kastelein,et al.  Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. , 2008, Journal of the American College of Cardiology.

[131]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[132]  Guiding the guidelines , 2011, The Lancet.

[133]  J Shepherd,et al.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.